These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29071066)

  • 21. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging.
    Zhang J
    J Neuroinflammation; 2015 May; 12():108. PubMed ID: 26022249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurological update: neuroimaging in dementia.
    Rittman T
    J Neurol; 2020 Nov; 267(11):3429-3435. PubMed ID: 32638104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent Updates on PET Imaging in Neurodegenerative Diseases].
    Kim YK
    Taehan Yongsang Uihakhoe Chi; 2022 May; 83(3):453-472. PubMed ID: 36238518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current and future prospects of nuclear medicine in dementia].
    Ito K; Inui Y; Kizawa T; Kimura Y; Kato T
    Rinsho Shinkeigaku; 2017 Sep; 57(9):479-484. PubMed ID: 28804110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.
    Shah M; Catafau AM
    J Nucl Med; 2014 Jun; 55(6):871-4. PubMed ID: 24833492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases.
    Meyer PT; Frings L; Hellwig S
    Curr Opin Neurol; 2014 Aug; 27(4):398-404. PubMed ID: 24978635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression.
    Teipel SJ; Buchert R; Thome J; Hampel H; Pahnke J
    Prog Neurobiol; 2011 Dec; 95(4):547-56. PubMed ID: 21601614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of PET brain imaging in the initial evaluation of dementia.
    Weaver JD; Espinoza R; Weintraub NT
    J Am Med Dir Assoc; 2007 Mar; 8(3):150-7. PubMed ID: 17349943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography imaging in dementia.
    Herholz K; Carter SF; Jones M
    Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid imaging.
    Villemagne VL; Rowe CC
    Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S41-9. PubMed ID: 21729418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The application of positron emission tomography (PET) imaging in CNS drug development.
    Suridjan I; Comley RA; Rabiner EA
    Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroimaging in dementias.
    de Souza LC; Lehéricy S; Dubois B; Stella F; Sarazin M
    Curr Opin Psychiatry; 2012 Nov; 25(6):473-9. PubMed ID: 23037962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Amyloid Imaging.
    Mallik A; Drzezga A; Minoshima S
    Semin Nucl Med; 2017 Jan; 47(1):31-43. PubMed ID: 27987555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand.
    Juréus A; Swahn BM; Sandell J; Jeppsson F; Johnson AE; Johnström P; Neelissen JA; Sunnemark D; Farde L; Svensson SP
    J Neurochem; 2010 Aug; 114(3):784-94. PubMed ID: 20477945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.